The Omnipod® 5 Advantage
No Need to Compromise Lifestyle Benefits for Clinical Results
With its powerful algorithm in every Pod, the Omnipod® 5 Automated Insulin Delivery (AID) System delivers strong glycemic results,1-3 a tube-free lifestyle, and the features patients want—all in a system that users agree is easy to use.4
And it’s simple to access with over 90% coverage,5 so there are fewer barriers between patients and better glycemic results.
Omnipod 5 real-world evidence demonstrated that type 1 and type 2 patients achieved over 80% time in range (TIR) with optimized settings.6 Find out how and discover more about the advantages of Omnipod 5, the #1 patient-requested and prescribed AID system in the U.S.,7,8 below.
Switching to Omnipod 5 From MDI Improved Results in Adults With T1D9
The RADIANT RCT was the first RCT to evaluate the transition from MDI to AID in patients who struggled with high A1C levels. Omnipod 5 improved TIR for adults, with a notable improvement for people with high A1Cs, who are often overlooked as candidates for AID.
26% TIR improvement on day 110
No increase in hypoglycemia9
57% of adult participants had an A1C ≥8% at baseline9
People With T2D Saw Strong Results3
SECURE-T2D is the first and most racially diverse11 study of AID in T2D published to date. Participants were reflective of the U.S. population living with T2D and saw improved glycemic outcomes3:
Lowered A1C by 2.1%*
Improved time in range by 20%— by nearly 5 hours per day
No increase in hypoglycemia
Maximize Outcomes With Omnipod 5
Strong results start with strong settings
53% of Omnipod 5 users not achieving glycemic targets do not frequently use the lowest Target Glucose setting of 110 mg/dL12
Real-world users increased TIR by switching from the highest to the lowest Target Glucose setting with no clinically meaningful impact on time below range13
Offer Patients Life Free From Tubes and Multiple Daily Injections
Omnipod 5 is the #1 patient-requested pump in the U.S.7 because of features like these:
Discreet, tubeless, and waterproof AID*
No visible needles with automatic cannula insertion—insulin delivery starts with just the push of a button
No need to disconnect from insulin during daily activities†
Simplified bolusing with the SmartBolus Calculator and the Custom Foods feature
Compatible with leading sensor brands
†Device components including the Pod, Sensor, and Transmitter must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components.
We Do Everything to Make It Simple to Access Omnipod 5
It’s easy for patients to try, start, and stay on Omnipod 5—with over 90% coverage, representing over 300 million covered lives.5
Covered under Medicare Part D
Omnipod 5 is the only tubeless AID system covered under Medicare Part D without a C-peptide test
Easy pharmacy access
Patients can get Pods when they pick up their insulin
Most U.S. patients pay under $30 per month14
Over 1/3 of U.S. patients pay $0 per month15
Do you have patients who would benefit from Omnipod® 5?
*The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®. WARNING: SmartAdjust™ technology should NOT be used by anyone under the age of 2 years old. SmartAdjust™ technology should also NOT be used in people who require less than 5 units of insulin per day, as the safety of the technology has not been evaluated in this population.
1. Brown S, et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6-70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time 70-180 mg/dL as measured by CGM in adults/adolescents and children, ST vs. 3-month Omnipod 5: 64.7% vs. 73.9%; 52.5% vs. 68.0%, P<0.0001, respectively.
2. Sherr JL, et al. 2022. 45(8):1907–1910. Prospective trial in 80 participants with T1D aged 2-5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (70-180mg/dL) in very young children (2-5.9 yrs) as measured by CGM: ST = 57.2%, 3-month Omnipod 5 = 68.1%, P<0.05.
3. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time in range (70-180 mg/dL): ST vs. 13-week Omnipod 5: 45% vs. 66%, P<0.001. Mean time <70 mg/dL as measured by CGM: ST = 0.2%, 3-month Omnipod 5 = 0.2%. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%).
4. Insulet Data on File. OP5-003 Clinical Study Report. 2024.13-week randomized, parallel-group clinical trial conducted among 194 adults (age 18-70) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 System versus pump therapy with CGM.
5. Reflects coverage for Omnipod 5 G6 Intro Kit and Omnipod 5 G6 Pods. Source: Managed Markets Insights & Technology, LLC, as of April 2025.
6. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014
7. Omnipod was the pump most frequently requested by people with type 1 and type 2 diabetes in a survey with Endocrinologists conducted by dQ&A across the United States. n=77 (T1) and n=63 (T2); H2 2024; P.25.
8. USA 2024, Data on file.
9. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. TBR (<70 mg/dL) at 13-weeks: non-inferiority was met with 2.56% TBR with Omnipod 5. Data on File. 2025. RF-042025-00020 & RF-052025-00033
10. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) [51% HbA1c≥ 8% (64 mmol/L)] with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Mean time in range (70-180 mg/dL) improvement of 26% on day 1 of using Omnipod 5. Data on file. RF-072025-00023
11. Pasquel FJ, et al. JAMA Network Open (2025). Race/ethnicity of participants reported as 24% Black, 22% Latino/Hispanic. Comparison based on published clinical trials of the current AID landscape in T2D. Insulet Data on File. RF-082024-00024
12. Insulet data on file. 2025. Retrospective analysis including 103,369 T1D users with TIR (3.9-10.0 mmol/L or 70-180 mg/dL) <70%. 54,365 (53%) did not use the 110mg/dL (6.1mmol/L) target as their average glucose target setting. RF-062025-00038
13. Real-world data from 403 people with type 1 diabetes aged 2+ using the Omnipod 5 System who transitioned from the 150 mg/dL to 110 mg/dL Target Glucose. Each Target Glucose was used for a consecutive period of 14-90 days. Median time in Range (70-180 mg/dL) improved 11.8% (P<0.05). Median time <70 mg/dL +0.23% (P<0.05). Omnipod 5 results based on users with ≥75% of days with ≥220 readings available. Data on File. 05.15.25. RF-042025-00013
14. Majority defined as at least 50% of patient co-pays $30 or less per month. Among All Paid Omnipod 5 G7G6 Pods Commercial and Medicare Claims from January 2024 to December 2024. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library.
15. Among All Paid Omnipod 5 G7 G6 Pods Commercial and Medicare Claims from January 2024 to December 2024. Includes benefits and offerings available through Insulet, such as the copay card program. Actual co-pay amount depends on patient’s health plan and coverage, they may fluctuate and be higher or lower than the advertised amount on a monthly basis. Source: IQVIA OPC Library.
INS-OHS-09-2025-00384 V1.0